Patents by Inventor Farid Bakir
Farid Bakir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6951878Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: May 28, 2002Date of Patent: October 4, 2005Assignee: Novo Nordisk A/SInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Publication number: 20050119332Abstract: The present invention provides novel compounds of formula 1a, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: ApplicationFiled: November 8, 2004Publication date: June 2, 2005Inventors: Lone Jeppesen, Henrik Andersen, Ole Olsen, Luke Judge, Daniel Holsworth, Farid Bakir, Frank Axe, Yu Ge
-
Publication number: 20050084506Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.Type: ApplicationFiled: August 6, 2004Publication date: April 21, 2005Inventors: Catherine Tachdjian, Andrew Patron, Sara Adamski-Werner, Farid Bakir, Qing Chen, Vincent Darmohusodo, Stephen Hobson, Xiaodong Li, Ming Qi, Daniel Rogers, Marketa Rinnova, Guy Servant, Xiao-Qing Tang, Mark Zoller, David Wallace, Amy Xing, Klaus Gubernator
-
Patent number: 6613903Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein X, R1, R2, R3, and R4 are defined more fully in the description. The compounds are useful in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.Type: GrantFiled: July 9, 2001Date of Patent: September 2, 2003Assignee: Novo Nordisk A/SInventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Moller, Ole Hvilsted Olsen, Frank Urban Axe, Farid Bakir, Yu Ge, Daniel Dale Holsworth, Luke Milburn Judge, Michael James Newman, Roy Teruyuki Uyeda, Barry Zvi Shapira
-
Publication number: 20030069267Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.Type: ApplicationFiled: May 28, 2002Publication date: April 10, 2003Inventors: Niels Peter Hundahl Moller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Publication number: 20020165398Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.Type: ApplicationFiled: April 19, 2002Publication date: November 7, 2002Inventors: Lone Jeppesen, Henrik Sune Andersen, Ole Hvilsted Olsen, Luke Milburn Judge, Daniel Dale Holsworth, Farid Bakir, Frank Urban Axe, Yu Ge
-
Publication number: 20020151561Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, 1Type: ApplicationFiled: July 9, 2001Publication date: October 17, 2002Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Moller, Ole Hvilsted Olsen, Frank Urban Axe, Farid Bakir, Yu Ge, Daniel Dale Holsworth, Luke Milburn Judge, Michael James Newman, Roy Teruyuki Uyeda, Barry Zvi Shapira
-
Publication number: 20020099073Abstract: The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP (TC-PTP), 1Type: ApplicationFiled: July 9, 2001Publication date: July 25, 2002Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Moller, Ole Hvilsted Olsen, Frank Urban Axe, Farid Bakir, Yu Ge, Daniel Dale Holsworth, Luke Milburn Judge, Michael James Newman, Roy Teruyuki Uyeda, Barry Zvi Shapira
-
Patent number: 6410586Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: March 16, 2001Date of Patent: June 25, 2002Assignees: Novo Nordisk A/S, Ontogen CorporationInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Patent number: 6388076Abstract: Y—X—C(R′)═C(R″)COOR′″ (A1) The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R′ and R″ are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl.Type: GrantFiled: August 24, 2000Date of Patent: May 14, 2002Assignee: Ontogen CorporationInventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
-
Publication number: 20020002199Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.Type: ApplicationFiled: March 11, 1999Publication date: January 3, 2002Inventors: LONE JEPPESEN, HENRIK SUNE ANDERSEN, OLE HVILSTED OLSEN, LUKE MILBURN JUDGE, DANIEL DALE HOLSWORTH, FARID BAKIR, FRANK URBAN AXE, YU GE
-
Patent number: 6262044Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: March 11, 1999Date of Patent: July 17, 2001Assignees: Novo Nordisk A/S, Ontogen CorporationInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Patent number: 6225329Abstract: The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like, wherein A, R1, R2, R3, R4, R16 and R17 are as defined in the specification.Type: GrantFiled: March 9, 1999Date of Patent: May 1, 2001Assignee: Novo Nordisk A/SInventors: Lutz Stefan Richter, Henrik Sune Andersen, Josef Vagner, Claus Bekker Jeppesen, Niels Peter Hundahl Møller, Sven Branner, Jing Su, Farid Bakir, Luke Milburn Judge
-
Patent number: 6150532Abstract: The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganism, eukaryoic cells, whole animals and human being. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R'" is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl. X is aryl. Y is selected from hydrogen or ##STR1## wherein (*) indicates a potential point of attachment to X.Type: GrantFiled: December 11, 1998Date of Patent: November 21, 2000Inventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
-
Patent number: 6123928Abstract: Novel polymeric biologically inert compositions and their intermediates, as well as sunscreen formulations comprising them and making them invisible, are provided for broad range protection from ultraviolet radiation. Acryl polymers comprising at least two different ultraviolet absorbing moieties having different light absorbing ranges are employed in conjunction with other monomers to provide sunscreen polymers as microparticles. The polymer microparticles, once imbibed with carrier compounds, change the refractive index, thus providing invisible sunscreen formulations which offer enhanced protection without adverse physiological effects.Type: GrantFiled: July 21, 1998Date of Patent: September 26, 2000Assignee: Biophysica, Inc.Inventors: Milos Sovak, Ronald C. Terry, James G. Douglass, III, Farid Bakir, Jason Brown, Peter Cugley
-
Patent number: 5965558Abstract: Y--X--C(R').dbd.C(R")COOR"'(A1)The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R"' is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl. X is aryl. Y is selected from hydrogen or ##STR1## wherein (*) indicates a potential point of attachment to X.Type: GrantFiled: October 29, 1997Date of Patent: October 12, 1999Assignee: Ontogen CorporationInventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
-
Patent number: 5753687Abstract: Y--X--C(R').dbd.C(R")COOR'" (A1)The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R'" is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl. X is aryl. Y is selected from hydrogen or ##STR1## wherein (*) indicates a potential point of attachment to X.Type: GrantFiled: December 16, 1996Date of Patent: May 19, 1998Assignee: Ontogen CorporationInventors: Adnan Mjalli, Sepehr Sarshar, Xiaodong Cao, Farid Bakir
-
Patent number: 5741924Abstract: Novel polymeric compositions and their intermediates are provided, providing for broad range protection from ultraviolet radiation. Acryl polymers comprising at least two different ultraviolet absorbing moieties having different light absorbing ranges are employed in conjunction with another hydrophilic monomer to provide sunscreen formulations for invisibility, and enhanced protection, without deleterious effects in the dermis.Type: GrantFiled: June 14, 1995Date of Patent: April 21, 1998Assignee: Biophysica Inc.Inventors: Milos Sovak, Ronald Calvin Terry, James Gordon Douglass, III, Farid Bakir
-
Patent number: 5487885Abstract: Novel polymeric compositions and their intermediates are provided, providing for broad range protection from ultraviolet radiation. Acryl polymers comprising at least two different ultraviolet absorbing moieties having different light absorbing ranges are employed in conjunction with another hydrophilic monomer to provide sunscreen formulations for invisibility, and enhanced protection, without deleterious effects in the dermis.Type: GrantFiled: December 9, 1993Date of Patent: January 30, 1996Assignee: Biophysica, Inc.Inventors: Milos Sovak, Ronald C. Terry, James G. Douglass, III, Farid Bakir